A Minimum 3‐Year Follow‐Up of Nivolumab‐Plus‐Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J‐ ENCORE Study

Key Points

• This research aims to evaluate the long-term effects of nivolumab-plus-ipilimumab in patients with advanced renal cell carcinoma.
• Conducted a minimum 3-year follow-up of patients treated with nivolumab-plus-ipilimumab.
• Included Japanese patients diagnosed with advanced or metastatic renal cell carcinoma.
• Utilized clinical trial registries for transparency and data collection.
• Demonstrated sustained efficacy of nivolumab-plus-ipilimumab over a 3-year period.
• Highlighted improved overall survival rates for patients receiving this combination therapy.
• Reported manageable safety profile throughout the treatment duration.